Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2002

View Archived Issues

Bay-41-4109: a novel anti-HBV candidate

Cannabinoids may not improve symptoms of multiple sclerosis

Safe transition from i.v. epoprostenol to s.c. treprostinil in patients with PAH

Therapeutic angiogenic effects of rFGF-2 in patients with intermittent claudication

CVT-3146 set to enter phase III in 2003

Eligix CD8-SC Cell Separation System approved in E.U.

Fujisawa announces microbial research agreement with MerLion

Fujirebio acquires rights to ovarian tumor markers

Amersham Biosciences and Sloan-Kettering Institute collaborate to scan human genome

Immune Network and AbNovo to develop antibody-based therapeutics for viral diseases

Levaquin sNDA submitted for chronic bacterial prostatitis

Incara's IND for liver cell therapy approved

Zonagen awarded SBIR grant for Progenta in breast cancer

Bristol-Myers Squibb researchers identify CDK-inhibitory semicarbazides

Japanese, American and British scientists jointly describe new PI3K inhibitors

New CDK inhibitors in early development at BMS

Roche presents A2A antagonists with potential in depression and other disorders

Versicor and Biosearch Italia to merge

Aventis describes novel factor Xa/VIIa inhibitors and their use

Novel tryptase inhibitors emerge from Boehringer Ingelheim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...